期刊文献+

TF双周方案治疗晚期胃癌的临床疗效探讨

Study and Analysis of Clinical Efficacy of TF Biweekly Regimen in the Treatment of Advanced Gastric Cancer
下载PDF
导出
摘要 目的分析TF双周方案的详细步骤,研究TF双周方案对于治疗晚期胃癌的临床效果。方法在本院2012年1月~2014年12月所治疗过的胃癌晚期患者中随机抽取60个病例作为本次TF双周方案治疗研究的研究对象,其中男性患者35例,女性患者25例,年龄在50~75岁。并将60个病例分为两组,一组使用TF双周方案治疗,另外一组使用常规胃癌晚期方案治疗,其他基础护理治疗措施均保持一致,观察并记录两组胃癌晚期患者在化疗过程中的临床表现及治疗效果。结果 TF双周方案组治疗的患者中,有15例患者病情有所好转,为有效治疗。5例患者出现恶心、食欲不振等现象,为无效治疗。常规治疗方案组治疗的患者中,有8例患者病情有所好转,剩余患者在治疗前后,未见明显差别。结论 TF双周方案对胃癌晚期有良好的治疗效果,有效率可达40%以上,适合胃癌晚期治疗。 Objective To analyze the biweekly regimen of TF,clinical effect of biweekly regimen for the treatment of advanced gastric cancer.Methods In our hospital in January 2012 to December 2014 and the treatment of patients with advanced gastric cancer were randomly selected 60 cases as the research object of the TF biweekly regimen in the treatment of research,including 35 cases of male patients,25 cases of female patients,age from 50 to 75.And 60 cases were divided into two groups,a group using TF biweekly regimen in the treatment of,another group using conventional advanced gastric cancer for treatment,other foundation treatment and nursing measures were consistent with observed and record the two groups of patients with advanced gastric cancer in chemotherapy of clinical manifestations and treatment effect.Results TF group of patients treated with biweekly regimen,15 patients improved,effective treatment.5 cases of patients with nausea,loss of appetite and other phenomena,invalid treatment.In the conventional treatment group,8 patients were improved,and the remaining patients had no significant difference before and after treatment.Conclusion TF biweekly regimen has good therapeutic effect on advanced gastric cancer,the efficiency is above 40%,suitable for the treatment of advanced gastric cancer.
作者 贺建功
机构地区 平顶山市中医院
出处 《中国继续医学教育》 2015年第17期87-88,共2页 China Continuing Medical Education
关键词 晚期胃癌 TF双周方案 治疗效果 Late gastric cancer TF biweekly regimen Treatment effect
  • 相关文献

参考文献6

二级参考文献40

  • 1Diaz Rubio E,Sastre J,Zaniboni A,et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase Ⅱ multicentric study[J]. Annals of Oncology, 1998, 9: 105 -108.
  • 2J onker D J, O' Callaghan C J, Karapetis C S, et al . Cetuximab for the treatment of colorectal cancer[J]. New Engl J Med, 2007,375:2040 -2048.
  • 3Diane B G, Delord J P, Philippe R, et al. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR[J]. Cancer Chemother Pharmacol, 2006,57 : 709-718.
  • 4Mahtani R L, Macdonald J S. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract[J]. Oncologist, 2008,13 : 39-50.
  • 5Tabernero J, Per Pfeiffer, Andres Cervantes. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? [J]. The Oncologist Gastrointestinal Cancer, 2008,13:113-119.
  • 6Pfeiffer P,Bjerregaard J K, Qvortrup C,et al. Simplification of cetuximab (Cet) administration: double dose every second week as a 60 minute infusion[J]. ASCO Meeting Abstracts, 2007,25 : 4133.
  • 7Tabernero J,Cervantes A,Martinelli E,et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pbarmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qlw) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) [J]. ASCO Meeting Abstracts,2006,24 : 3085.
  • 8Cunningham D, Humbler Y,Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic cancer[J]. N Engl J Med,2004,351(4):337-345.
  • 9Souglakos J, Kalykaki A, Vamvakas L, et al. Phase Ⅱ trail of capectiabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin based chemotherapy[J]. Ann Oncol, 2007,18(2) : 305- 310.
  • 10Shuichi Hironaka,Sadamoto Zenda,Narikazu Boku,Akira Fukutomi,Takayuki Yoshino,Yusuke Onozawa.Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer[J]. Gastric Cancer . 2006 (1)

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部